Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

• Main Authors: Yutaro Kaneko (Author), Ryo Hatano (Author), Naoto Hirota (Author), Nicolas Isambert (Author), Véronique Trillet-Lenoir (Author), Benoit You (Author), Jérôme Alexandre (Author), Gérard Zalcman (Author), Fanny Valleix (Author), Thomas Podoll (Author), Yoshimi Umezawa (Author), Seiichi Takao (Author), Satoshi Iwata (Author), Osamu Hosono (Author), Tetsuo Taguchi (Author), Taketo Yamada (Author), Nam H. Dang (Author), Kei Ohnuma (Author), Eric Angevin (Author), Chikao Morimoto (Author)
• Format: Book
• Published: BMC, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Methods Box and Whisker plot analysis, Scat...